Recent Updates
Recently added Catalysts

JNJ-42396302

Phase 1

Healthy | Small molecule | Other |Johnson & Johnson|Last Updated: Sep 10, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment18

FDA Designations

No designations recorded

Clinical trial landscape

JNJ-42396302 · 1 trial · 1 indication

Phase 1 1
NCT01732237A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male ParticipantsHealthy
COMPLETED18 Analytics
PHASE1COMPLETED
A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants
Healthy
NCT0173223718
Unlock trial analytics

Study Endpoints

Primary Endpoints

Maximum observed plasma analyte concentration (Cmax) of JNJ-42396302
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Area under the plasma concentration time curve for JNJ-42396302
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Actual sampling time to reach the maximum plasma analyte concentration (tmax) of JNJ-42396302
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Apparent terminal elimination half-life of JNJ-42396302
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Maximum observed plasma analyte concentration (Cmax) of JNJ-53773187
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Area under the plasma concentration time curve for JNJ-53773187
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Actual sampling time to reach the maximum plasma analyte concentration (tmax) of JNJ-53773187
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Apparent terminal elimination half-life of JNJ-53773187
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Maximum observed plasma analyte concentration (Cmax) of JNJ-42692507
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Area under the plasma concentration time curve for JNJ-42692507
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Actual sampling time to reach the maximum plasma analyte concentration (tmax) of JNJ-42692507
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours
Apparent terminal elimination half-life of JNJ-42692507
10, 20, 30, and 45 minutes; 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, and 72 hours

Secondary Endpoints

Number of patients with adverse events
within 7 days after the last dose of the study medication
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
JNJ-42396302EXPERIMENTALPatients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
JNJ-42692507EXPERIMENTALPatients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
JNJ-53773187EXPERIMENTALPatients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.

Interventions

NameTypeDescription
JNJ-42396302DRUGA single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
JNJ-42692507DRUGA single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
JNJ-53773187DRUGA single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexMALE
Healthy VolunteersYes

Inclusion Criteria: * Participant should be healthy male on the basis of physical examination, medical history, vital signs, electrocardiogram, the results of blood biochemistry and hematology tests and a urinalysis * Participant must have a Body Mass Index of 18.5 to 30.0 kg/m2 * Have a blood pres...

Unlock Eligibility Criteria

Frequently asked questions about JNJ-42396302

What is JNJ-42396302 used for?

JNJ-42396302 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics in healthy male participants. The drug is not approved and remains under investigation.

Who makes JNJ-42396302?

JNJ-42396302 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is an investigational small molecule currently in Phase 1 clinical development.

What phase is JNJ-42396302 in?

JNJ-42396302 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved for any use.

What clinical trials is JNJ-42396302 in?

JNJ-42396302 has one completed clinical trial, NCT01732237, titled 'A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants.' This Phase 1 study enrolled 18 healthy male participants aged 18 years and older.

Is JNJ-42396302 the same as JNJ-53773187 or JNJ-42692507?

No, JNJ-42396302 is a distinct investigational drug. It was studied alongside JNJ-53773187 and JNJ-42692507 in a single clinical trial, NCT01732237, which evaluated the pharmacokinetics of all three compounds in healthy male participants.